LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial

作者：R. Dent, Zhi-Ming Shao, P. Schmid, J. Cortés, David W. Cescon, Shigehira Saji, Kyung Hae Jung, T. Bachelot, S. Wang, Ğüvenç Başaran, Y.S. Chae, R.M. Mathiba, S-C. Chen, A. Stradella, N. Battelli, Naoki Niikura, Kangning Zhao, P. Vuković, M. Maxwell, T. Traina · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.09.031 · 被引用次数：30 · 研究领域：HER2/EGFR in Cancer Research、Advanced Breast Cancer Therapies、Breast Cancer Treatment Studies